Latest filings (excl ownership)
8-K/A
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
1 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 24
8-K
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
12 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 23
8-K
Departure of Directors or Certain Officers
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
28 Sep 23
8-K
Other Events
30 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
14 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Jul 23
8-K
Atossa Therapeutics Announces $10M Stock Repurchase Program
28 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Jun 23
8-K
Departure of Directors or Certain Officers
1 Jun 23
8-K
Changes in Registrant's Certifying Accountant
22 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
15 May 23
8-K
Submission of Matters to a Vote of Security Holders
4 May 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
8-K
Amendments to Articles of Incorporation or Bylaws
26 Apr 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Apr 23
ARS
2022 FY
Annual report to shareholders
30 Mar 23
DEF 14A
Definitive proxy
30 Mar 23
10-K
2022 FY
Annual report
22 Mar 23
8-K
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update
22 Mar 23
8-K
Other Events
13 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
7 Nov 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Oct 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8 Aug 22
8-K
Other Events
7 Jul 22
8-K
Regulation FD Disclosure
1 Jul 22
8-K
Regulation FD Disclosure
6 Jun 22
8-K
Submission of Matters to a Vote of Security Holders
16 May 22
10-Q
2022 Q1
Quarterly report
9 May 22
8-K
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
9 May 22
Latest ownership filings
4
Jonathan Finn
11 Apr 24
4
Tessa Cigler
14 Mar 24
3
Tessa Cigler
14 Mar 24
4
GREGORY L WEAVER
17 Nov 23
4/A
Jonathan Finn
15 Nov 23
3
Jonathan Finn
15 Nov 23
4
Jonathan Finn
15 Nov 23
3
Heather Rees
16 Oct 23
4
GREGORY L WEAVER
20 Jun 23
4
GREGORY L WEAVER
5 Jun 23
4
GREGORY L WEAVER
5 May 23
4
H. Lawrence Remmel
5 May 23
4
Richard I Steinhart
5 May 23
4
Shu-Chih Chen
5 May 23
4
Stephen J Galli
5 May 23
4
STEVEN C QUAY
6 Mar 23
4
Kyle Guse
6 Mar 23
SC 13G/A
VANGUARD GROUP INC
9 Feb 23
SC 13G
BlackRock Inc.
8 Jul 22
4
Shu-Chih Chen
16 May 22
4
Stephen J Galli
16 May 22
4
H. Lawrence Remmel
16 May 22
4
Richard I Steinhart
16 May 22
4
GREGORY L WEAVER
16 May 22
4
Kyle Guse
28 Feb 22
4
STEVEN C QUAY
28 Feb 22
SC 13G/A
CVI Investments, Inc.
14 Feb 22
SC 13G
VANGUARD GROUP INC
9 Feb 22
SC 13G
BlackRock Inc.
4 Feb 22
SC 13G/A
Empery Asset Management, LP
13 Jan 22
4
GREGORY L WEAVER
7 Jul 21
4
Stephen J Galli
18 May 21
4
STEVEN C QUAY
18 May 21
4
Kyle Guse
18 May 21
4
Shu-Chih Chen
18 May 21
4
STEVEN C QUAY
18 May 21
4
H. Lawrence Remmel
18 May 21
4
GREGORY L WEAVER
18 May 21
4
Richard I Steinhart
18 May 21
SC 13G
INTRACOASTAL CAPITAL, LLC
15 Jan 21